Literature DB >> 12217423

The effects of acute and chronic alpha melanocyte stimulating hormone (alphaMSH) on cardiovascular dynamics in conscious rats.

Crystal Hill1, Joseph C Dunbar.   

Abstract

Alpha melanocyte stimulating hormone (alphaMSH) has been demonstrated to have regulatory functions in the periphery and central nervous system (CNS). alphaMSH plays a central role in the regulation of metabolic balance such as decreasing food intake, increasing sympathetic outflow and hypothalamic/pituitary function. Our laboratory has investigated the actions of alphaMSH on sympathetic and cardiovascular dynamics using anesthetized animals. In this study we determined both the acute and chronic effects of alphaMSH on cardiovascular and metabolic dynamics in conscious unrestrained rats. Animals were each implanted with a radio-telemetry transmitter for recording of cardiovascular parameters and subsequently instrumented with intracerebroventricular (ICV) cannulas. The acute ICV administration of alphaMSH significantly increased the mean arterial pressure (MAP) and heart rate (HR) when compared to artificial cerebrospinal fluid (ACSF) controls. On the other hand chronic alphaMSH infusion resulted in an initial increase in MAP and HR lasting for 2 days followed by a decrease in MAP. Chronic alphaMSH administration decreased physical activity and food intake but not weight gain. We conclude that in the conscious unrestrained animal the acute administration of alphaMSH increased MAP and HR, however, chronic infusion is associated with decreased MAP, physical activity and food intake.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217423     DOI: 10.1016/s0196-9781(02)00103-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  12 in total

1.  Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

Authors:  F M Rabey; R S V S Gadepalli; S Diano; Q Cheng; T Tabrizian; D Gailani; J M Rimoldi; Z Shariat-Madar
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Limiting feeding to the active phase reduces blood pressure without the necessity of caloric reduction or fat mass loss.

Authors:  Isabelle Cote; Hale Z Toklu; Sara M Green; Drake Morgan; Christy S Carter; Nihal Tümer; Philip J Scarpace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-07-19       Impact factor: 3.619

Review 3.  Role of the brain melanocortins in blood pressure regulation.

Authors:  Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Taolin Fang; Nicola Aberdein; Cecilia E Perez de Lara; John E Hall
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-06       Impact factor: 5.187

Review 4.  The melanocortin pathway and control of appetite-progress and therapeutic implications.

Authors:  Giulia Baldini; Kevin D Phelan
Journal:  J Endocrinol       Date:  2019-04-01       Impact factor: 4.286

Review 5.  Cardiovascular effects of melanocortins.

Authors:  Michael H Humphreys; Xi-Ping Ni; David Pearce
Journal:  Eur J Pharmacol       Date:  2011-01-01       Impact factor: 4.432

6.  Neuronostatin acts in brain to biphasically increase mean arterial pressure through sympatho-activation followed by vasopressin secretion: the role of melanocortin receptors.

Authors:  Gina L C Yosten; Alicia T Pate; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-16       Impact factor: 3.619

7.  Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study.

Authors:  Maria Baltazi; Niki Katsiki; Christos Savopoulos; Fotios Iliadis; George Koliakos; Apostolos I Hatzitolios
Journal:  Am J Cardiovasc Dis       Date:  2011-05-20

8.  Microinjections of alpha-melanocyte stimulating hormone into the nucleus ambiguus of the rat elicit vagally mediated bradycardia.

Authors:  Vineet C Chitravanshi; Suresh Bhatt; Hreday N Sapru
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-18       Impact factor: 3.619

9.  AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality.

Authors:  K Doi; X Hu; P S T Yuen; A Leelahavanichkul; H Yasuda; S M Kim; J Schnermann; T E N Jonassen; J Frøkiaer; S Nielsen; R A Star
Journal:  Kidney Int       Date:  2008-03-19       Impact factor: 10.612

Review 10.  The effects of beta-endorphin: state change modification.

Authors:  Jan G Veening; Henk P Barendregt
Journal:  Fluids Barriers CNS       Date:  2015-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.